You are viewing the site in preview mode

Skip to main content

Advertisement

Table 3 characteristics of the prescriptions

From: Systemic fluoroquinolone prescriptions for hospitalized children in Belgium, results of a multicenter retrospective drug utilization study

FQ prescribed Ciprofloxacin: 253 (96.6%)
Moxifloxacin: 3 (1.1%)
Levofloxacin: 5 (1.9%)
Norfloxacin: 1 (0.4%)
Main indication On-label
Respiratory infections in CF patients: 13 (5.0%)
Complicated UTI and pyelonephritis: 31 (11.8%)
Off-label
Prophylaxis of febrile neutropenia: 49 (18.7%)
Pneumonia: 34 (13.0%)
Multidrug-resistant tuberculosis: 1 (0.4%)
Sepsis: 6 (2.3%)
Ocular trauma: 1 (0.4%)
Intraabdominal abcess and peritonitis: 15 (5.7%)
Enteritis: 13 (5.0%)
Meningitis and/or encephalitis: 65 (24.8%)
Epididymitis: 2 (0.8%)
Skin and soft tissue infections: 27 (10.3%), including burns and surgical site infections
Osteomyelitis: 2 (0.8%)
Q-fever: 1 (0.4%)
Microbial cultures None: 170 (64.9%)
Pseudomonas aeruginosa: 51 (19.5%)
Colonic bacteriae: 17 (6.5%)
(Escherichia coli, Enterobacter cloaca, Citrobacter freundi)
Stenotrophomonas maltophilia: 7 (2.7%)
Salmonalla species (blood culture): 3 (1.1%)
Klebsiella pneumoniae: 4 (1.5%)
Mycoplasma pneumoniae: 2 (0.8%)
Mycobacterium tuberculosis: 1 (0.4%)
Acinetobacter species: 1 (0.4%)
Proteus mirabilis: 1 (0.4%)
Neiseria meningitidis, serogroup B: 1 (0.4%)
Morganella morgani: 1 (0.4%)
Route of administration Orally: 130 (49.6%)
IV: 132 (50.4%)
Doses per day 1: 5 (1.9%)
2: 240 (91.6%)
3: 17 (6.5%)
Dose adequate: Adequate: 183 (69.8%)
Inadequate: 79 (30.2%)
Underdosing: 45 (56.9%)
Overdosing: 25 (31,6%)
Unnecessarily thrice daily dosing PO: 9 (11,4%)